[{"orgOrder":0,"company":"Mercy Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Antibiotic","year":"2018","type":"Inapplicable","leadProduct":"Cefazolin","moa":"Bacterial penicillin-binding protein","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"Mercy Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mercy Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Mercy Health \/ Undisclosed"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"SWITZERLAND","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Diclofenac Potassium","moa":"Cyclooxygenase","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Rundo International Pharmaceutical Research & Development","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Indomethacin","moa":"Cyclooxygenase","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Rundo International Pharmaceutical Research & Development","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ Rundo International Pharmaceutical Research & Development"},{"orgOrder":0,"company":"Northwell Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Naproxen","moa":"Cyclooxygenase","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"Northwell Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Northwell Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Northwell Health \/ Undisclosed"},{"orgOrder":0,"company":"Seoul National University Bundang Hospital","sponsor":"JW Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"SOUTH KOREA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Ferric Carboxymaltose","moa":"Fe","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"Seoul National University Bundang Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seoul National University Bundang Hospital \/ JW Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"Seoul National University Bundang Hospital \/ JW Pharmaceutical"},{"orgOrder":0,"company":"International Clinical Research Institute","sponsor":"Mallinckrodt Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"International Clinical Research Institute","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"International Clinical Research Institute \/ Mallinckrodt Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"International Clinical Research Institute \/ Mallinckrodt Pharmaceuticals"},{"orgOrder":0,"company":"Universitaire Ziekenhuizen KU Leuven","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"BELGIUM","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Rocuronium Bromide","moa":"Muscle-type nicotinic acetylcholine receptor","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"Universitaire Ziekenhuizen KU Leuven","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Universitaire Ziekenhuizen KU Leuven \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Universitaire Ziekenhuizen KU Leuven \/ Merck & Co"},{"orgOrder":0,"company":"Sanford Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Hydrocodone Bitartrate","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"Sanford Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanford Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Sanford Health \/ Undisclosed"},{"orgOrder":0,"company":"Hvidovre University Hospital","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"DENMARK","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Parathyroid Hormone (1-84)","moa":"Parathyroid hormone-1 receptor","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"Hvidovre University Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hvidovre University Hospital \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"Hvidovre University Hospital \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"University of Manitoba","sponsor":"Health Sciences Centre Winnipeg","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"CANADA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Vancomycin Hydrochloride","moa":"Peptidoglycan","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"University of Manitoba","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Manitoba \/ Health Sciences Centre Winnipeg","highestDevelopmentStatusID":"11","companyTruncated":"University of Manitoba \/ Health Sciences Centre Winnipeg"},{"orgOrder":0,"company":"UConn Health","sponsor":"Orthopedic Research and Education Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Plasminogen","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"UConn Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"UConn Health \/ Orthopedic Research and Education Foundation","highestDevelopmentStatusID":"11","companyTruncated":"UConn Health \/ Orthopedic Research and Education Foundation"},{"orgOrder":0,"company":"Campbell Clinic","sponsor":"Duke University | The University of Pittsburgh School of Medicine | Endeavor Health | University of Cincinnati | Washington University School of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Plasminogen","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"Campbell Clinic","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Campbell Clinic \/ Duke University | The University of Pittsburgh School of Medicine | Endeavor Health | University of Cincinnati | Washington University School of Medicine","highestDevelopmentStatusID":"11","companyTruncated":"Campbell Clinic \/ Duke University | The University of Pittsburgh School of Medicine | Endeavor Health | University of Cincinnati | Washington University School of Medicine"},{"orgOrder":0,"company":"Inspire Health Medical Group","sponsor":"Arbi Nazarian, MD","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Plasminogen","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"Inspire Health Medical Group","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inspire Health Medical Group \/ Arbi Nazarian, MD","highestDevelopmentStatusID":"11","companyTruncated":"Inspire Health Medical Group \/ Arbi Nazarian, MD"},{"orgOrder":0,"company":"Kendall Healthcare Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Lidocaine","moa":"Sodium channel alpha subunit","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"Kendall Healthcare Group","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kendall Healthcare Group \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Kendall Healthcare Group \/ Undisclosed"},{"orgOrder":0,"company":"Prisma Health-Upstate","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Mepivacaine Hydrochloride","moa":"Sodium channel alpha subunit","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"Prisma Health-Upstate","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prisma Health-Upstate \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Prisma Health-Upstate \/ Undisclosed"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pacira BioSciences \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Pacira BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Academisch Medisch Centrum - Universiteit van Amsterdam","sponsor":"ZonMw","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"NETHERLANDS","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"Academisch Medisch Centrum - Universiteit van Amsterdam","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Academisch Medisch Centrum - Universiteit van Amsterdam \/ ZonMw","highestDevelopmentStatusID":"11","companyTruncated":"Academisch Medisch Centrum - Universiteit van Amsterdam \/ ZonMw"},{"orgOrder":0,"company":"Northern Light Mercy Hospital","sponsor":"MaineHealth","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"Northern Light Mercy Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Northern Light Mercy Hospital \/ MaineHealth","highestDevelopmentStatusID":"11","companyTruncated":"Northern Light Mercy Hospital \/ MaineHealth"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Bupivacaine Hydrochloride","moa":"Sodium channel protein type IV alpha subunit","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"Virtua Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"5CC Vivigen","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"Virtua Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Virtua Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Virtua Health \/ Undisclosed"},{"orgOrder":0,"company":"Seton Healthcare Family","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"BIO4","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"Seton Healthcare Family","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seton Healthcare Family \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Seton Healthcare Family \/ Undisclosed"},{"orgOrder":0,"company":"Hospital Clinic of Barcelona","sponsor":"Abbott Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"SPAIN","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2013","type":"Inapplicable","leadProduct":"HMB","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"Hospital Clinic of Barcelona","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hospital Clinic of Barcelona \/ Abbott Laboratories","highestDevelopmentStatusID":"11","companyTruncated":"Hospital Clinic of Barcelona \/ Abbott Laboratories"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"IPACK Block","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"Odense University Hospital","sponsor":"Independent Research Fund Denmark","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"DENMARK","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Macrogol 3350","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"Odense University Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Odense University Hospital \/ Independent Research Fund Denmark","highestDevelopmentStatusID":"11","companyTruncated":"Odense University Hospital \/ Independent Research Fund Denmark"},{"orgOrder":0,"company":"Seton Healthcare Family","sponsor":"Celling Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Solum Iv","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"Seton Healthcare Family","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seton Healthcare Family \/ Celling Biosciences","highestDevelopmentStatusID":"11","companyTruncated":"Seton Healthcare Family \/ Celling Biosciences"},{"orgOrder":0,"company":"GCS Ramsay Sant\u00e9","sponsor":"Euraxi Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"FRANCE","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"GCS Ramsay Sant\u00e9","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GCS Ramsay Sant\u00e9 \/ Euraxi Pharma","highestDevelopmentStatusID":"11","companyTruncated":"GCS Ramsay Sant\u00e9 \/ Euraxi Pharma"},{"orgOrder":0,"company":"Henry Ford Health System","sponsor":"SMITH & NEPHEW INC","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"Henry Ford Health System","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Implant","sponsorNew":"Henry Ford Health System \/ SMITH & NEPHEW INC","highestDevelopmentStatusID":"11","companyTruncated":"Henry Ford Health System \/ SMITH & NEPHEW INC"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Olayemi Osiyemi MD","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Ceftaroline Fosamil","moa":"Bacterial penicillin-binding protein","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forest Laboratories \/ Olayemi Osiyemi MD","highestDevelopmentStatusID":"11","companyTruncated":"Forest Laboratories \/ Olayemi Osiyemi MD"},{"orgOrder":0,"company":"Roche Diagnostics GmbH","sponsor":"Lene Bergendal Solberg","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"GERMANY","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Zoledronic Acid","moa":"Farnesyl diphosphate synthase","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"Roche Diagnostics GmbH","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Roche Diagnostics GmbH \/ Lene Bergendal Solberg","highestDevelopmentStatusID":"11","companyTruncated":"Roche Diagnostics GmbH \/ Lene Bergendal Solberg"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Valera Bussell","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Milnacipran","moa":"Norepinephrine transporter","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Forest Laboratories \/ Valera Bussell","highestDevelopmentStatusID":"11","companyTruncated":"Forest Laboratories \/ Valera Bussell"},{"orgOrder":0,"company":"Radius Health","sponsor":"Daniel Horwitz","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Abaloparatide","moa":"Parathyroid hormone receptor","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"Radius Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Radius Health \/ Daniel Horwitz","highestDevelopmentStatusID":"11","companyTruncated":"Radius Health \/ Daniel Horwitz"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Shane Burch","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Teriparatide","moa":"Parathyroid hormone receptor","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Shane Burch","highestDevelopmentStatusID":"11","companyTruncated":"Eli Lilly \/ Shane Burch"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Jose Soberon","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pacira BioSciences \/ Jose Soberon","highestDevelopmentStatusID":"11","companyTruncated":"Pacira BioSciences \/ Jose Soberon"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Sponsor :
Duke University | The University of Pittsburgh School of Medicine | Endeavor Health | University of Cincinnati | Washington University School of Medicine
Details :
Tranexamic Acid is a Other Small Molecule drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Anterior Cruciate Ligament Injuries.
Sponsor :
Duke University | The University of Pittsburgh School of Medicine | Endeavor Health | University of Cincinnati | Washington University School of Medicine
Details :
Tranexamic Acid is a Other Small Molecule drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Long Bone Fractures.
Details :
Vancomycin is a Antibiotic drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Fractures, Open.
Details :
Macrogol 3350 is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hip Fractures.
Details :
Mepivacaine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Arthroplasty, Replacement, Knee.
Details :
Bupivacaine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Arthroplasty, Replacement, Knee.
Details :
Ferinject (Ferric Carboxymaltose) is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hip Fractures.
Details :
IPACK Block is a drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Anterior Cruciate Ligament Injuries.
Details :
Zoledronic Acid is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hip Fractures.
Reset All
